Publication: Safety and immunogenicity of REMUNE(TM) in HIV-infected Thai subjecgts
1
Issued Date
1998-01-01
Resource Type
ISSN
0264410X
Other identifier(s)
2-s2.0-0031986269
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine. Vol.16, No.2-3 (1998), 142-149
Suggested Citation
Anuwat Limsuwan, Vina Churdboonchart, Ronald B. Moss, Worachart Sirawaraporn, Reungpung Sutthent, Buranaj Smutharaks, David Glidden, Richard Trauger, Georgia Theofan, Dennis Carlo Safety and immunogenicity of REMUNE(TM) in HIV-infected Thai subjecgts. Vaccine. Vol.16, No.2-3 (1998), 142-149. doi:10.1016/S0264-410X(97)88327-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/18327
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Safety and immunogenicity of REMUNE(TM) in HIV-infected Thai subjecgts
Other Contributor(s)
Abstract
The safety and immunogenicity of REMUNE(TM), an HIv-specific immune based therapy for HIV infection, was evaluated in a cohort of 30 HIV infected subjects in Thailand. This therapy utilizes a gp120 depleted inactivated virus (HZ321), which exhibits a high degree of conservation with the core antigens of both type B' and E strains of HIV the predominant Thailand isolates. The treatment was well tolerated, with no serious adverse events reported over the course of the 4-month trial. Treatment in which four doses were administered with REMUNE(TM) appeared to boost HIV-specific immune responses, with approximately 75% of the treated subjects demonstrating an increase in either the repertoire or the intensity of the serological response to HIV as measured by Western blot. CD4%, viral load, and weight remained stable over the course of the 4-month study relative to baseline values. Viral subtyping of this cohort revealed a predominance of type 'E'. These data suggest that REMUNE(TM) is safe and immunogenic in seropositive Thai subjects and supports further study of the therapeutic potential of REMUNE(TM) to treat HIV-1 infection.